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In patients with transfusion-dependent beta thalassaemia
major, transfusions and iron chelation therapy with
desferrioxamine (DFO) have signiﬁcantly improved the
survival, ameliorated clinical features and reduced mor-
bidity (1–4). However, cardiac complications are still
responsible for signiﬁcant morbidity and remain the lead-
ing cause of mortality (2). In some cases, these were
because of difﬁculty in accepting the chelation treatment,
which was cumbersome (5), but also occurred even in
some patients who accepted the chelation therapy well
(6, 7).
Effectiveness of chelation is progressively improving,
especially during the last decade, with the introduction
of two oral chelators, deferiprone (DFP) and deferasirox
(DFX). There are now more choices with respect to the
provision of iron chelation therapy. Each chelator can be
given as monotherapy and DFP and DFO have been
administered widely in combination.
Since 2000, a number of observational studies have
indicated an improvement in overall survival with reduc-
tion of deaths caused by cardiac disease (8, 9). In addi-
tion, two studies demonstrated that the incidence of
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ª 2010 John Wiley & Sons A/S 335cardiac disease and cardiac-related death were higher in
patients who continued treatment with DFO compared
to those who switched to DFP (10, 11). In addition
to the broader therapeutic choices, newer assessment
techniques for monitoring iron concentration have been
developed and provide a means of accurately assessing
iron overload in various organs. In particular, magnetic
resonance imaging (MRI) has allowed more accurate
assessment of liver and myocardial iron overload.
The initial objective of this observational study was
to determine whether the availability of new treatment
regimes and the ability to determine organ-speciﬁc iron
load have had an impact on survival. The new treat-
ment regimes include the availability of oral iron chela-
tors. The organ-speciﬁc assessment of iron load is now
available, particularly for the heart by T2* estimation
by cardiac magnetic resonance (CMR) (12). We there-
fore calculated and compared the risk of cardiac death
over two distinct time periods: 1990–1999 and 2000–
2008. During the ﬁrst time period, DFO was the only
chelator available in our unit, while after 2000 other
chelation options, mainly DFP and combination ther-
apy with DFP and DFO (Combination), became avail-
able for thalassaemia patients. The next step was to
analyse and compare cardiac morbidity and mortality
as well as improvement of existing cardiac disease in
patients receiving DFO, DFP and Combination after
the year 2000. We also sought to analyse other factors
that inﬂuence the incidence of cardiac events or reversal
of heart disease including age, sex and severity of
haemosiderosis.
With respect to DFX, a limited amount of data has
been available to date as it was licensed in Europe <3 yr
ago. For this reason, we did not include DFX in a com-
parison analysis but rather reported preliminary results
in preventing and reversing cardiac morbidity and possi-
bly mortality.
Patients and methods
In our unit, currently, more than 400 patients with thal-
assaemia are treated with regular blood transfusions at
15–21 d intervals, chelation therapy and appropriate
monitoring. Pretransfusion haemoglobin (Hb) levels are
maintained above 95 g⁄L. Chelation regimes include
DFO at doses of 20–40 mg⁄kg per infusion with at least
three (3–5) infusions per week, DFP at 75–100 mg⁄kg
per day in three divided doses, combinations of the two
with DFP daily and DFO with similar doses as with
monotherapy, 8–24 hourly infusions⁄3–7 times per week.
After 2007, when DFX was licensed, it was also given in
our unit as monotherapy at doses of 15–30 mg⁄kg per
day. In some selected cases, DFX was also administered
with doses of up to 40 mg⁄kg per day.
Iron load is traditionally assessed by regular measure-
ment of ferritin levels. Over the last 8 years cardiac and
hepatic MRI has been increasingly utilised to evaluate,
indirectly, the degree of cardiac and hepatic iron loading.
In general patients are assessed annually for cardiac
function by symptomatology, clinical examination, chest
X-rays, ECGs and echocardiography. Some patients were
reluctant to have these assessments.
The decisions for the chelation regime and the doses
of the drugs prescribed were based on parameters reﬂect-
ing iron overload (2, 12, 13), cardiac status and other
iron-related morbidities. We prescribed combination
therapy in patients in whom we had a high level of con-
cern with respect to their iron load, i.e. very high ferritin
levels, liver iron concentration (LIC) or cardiac iron
as shown by MRI and in patients with obvious cardiac
dysfunction. We prescribed the maximum doses and
frequency of use of the chelators for those patients with
cardiac dysfunction. Individual patients’ personal
preferences were also taken into consideration.
As cardiac morbidity and mortality (4, 14) in patients
with thalassaemia have been linked to age, gender and
severity of iron load, demographic data (date of birth
and gender) and annual mean ferritin levels were
recorded. Patients were classiﬁed according to their mean
ferritin levels for each calendar year into three groups as
follows: mild haemosiderosis: <2000 lg⁄L, moderate:
2000–4000 lg⁄L and severe: >4000 lg⁄L. Three age
groups were also formed: 10–20, 20–30 and >30 yr.
For the comparison of the risk of cardiac death
between 1990–1999 and 2000–2008, all patients with thal-
assaemia were included regardless of the chelation regime.
The risk of cardiac death was evaluated in two age
groups for each time period; those aged 20–30 yr and
those 30–40 yr. This stratiﬁcation was applied to compare
similar age groups over the two time periods and to elimi-
nate possible bias because of including patients less prone
to iron-related cardiac death in the second time period.
Cardiac disease is rare before the age of 10 yr. There-
fore, for the assessment of the incidence of de novo cardiac
events according to the chelation regime, all patients with
thalassaemia older than 10 yr and free of cardiac disease
on 1 January 1999, who were on DFO, DFP or Combina-
tion, were included. Those who reached the 10th year of
age after that date were subsequently included when
reaching that age. The year 1999 was chosen because it
was the last during which all patients in the study exclu-
sively received DFO. After 2000 most patients continued
on DFO including those with severe cardiac iron loading.
Subsequently, progressively more patients with severe iron
load were preferentially prescribed Combination or DFP.
In this way, during the last 10 yr, a sufﬁcient number of
patients from each group of severity participated in those
three treatment groups. DFX has been used in our unit
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monotherapy, mainly in patients with mild iron load
according to ferritin levels. This policy could introduce a
systematic bias as this group of patients would selectively
consist of milder cases than those patients included in the
other three regimes. For this reason, patients on DFX
were excluded from the comparative analysis. The end
point of the de novo cardiac event analysis was the devel-
opment of a cardiac event or the 31 December 2008, if no
cardiac event occurred. In this document, the terms ‘car-
diac disease’, ‘cardiac dysfunction’ and ‘cardiac event’ are
used interchangeably.
A de novo cardiac event was deﬁned as either of the
following:
l Prescription of cardiac medication by cardiologists
for clinically evident heart failure, after they had fully
assessed their cardiac status as described earlier.
l Cardiac death without pre-existing evidence of heart
disease.
Cardiac medications included angiotensin-converting
enzyme inhibitors, angiotensin receptor blockers, digoxin
and beta-blockers. Diuretics were considered as cardiac
medication only when given in conjunction with other
cardiac medications. In thalassaemia, some patients are
treated with diuretics for the management of hypercalcu-
ria and not as a cardiac medication.
The analyses were conducted according to single calen-
dar year intervals between 1 January 1999 and 31
December 2008. Our main approach was to evaluate the
probability (risk) of developing a cardiac event for each
chelation regime in each calendar year. This risk was cal-
culated by dividing the number of new cardiac events in
each regime by the total number of patients attributed to
that regime for each calendar year. Each patient was
included as receiving one particular regime during each
year. In switching between regimes, the following rules
were imposed when attributing patients to a particular
group: For each calendar year, the patients were assigned
to the particular treatment regime they received for the
longest period provided that it lasted for at least
6 months of that year. On this basis, 18 patients were
excluded, none of whom developed a cardiac event dur-
ing this period. On identiﬁcation of a cardiac event, this
was attributed to the regime the patient was receiving for
the longest period during the previous 12 months. For
the estimation of exact incidence rates for each regime,
the events were also analysed according to the regime
received at the time of each event.
The risk of cardiac death in relation to the chelation
regime was also evaluated. Each cardiac death was
attributed to the regime the patient was receiving for the
longest period during the 12 months before death.
All patients who developed a de novo cardiac event
after 1999 as well as those with evidence of cardiac
disease prior to 1999 were included in the improvement
component of the analysis. Exceptions were patients who
experienced sudden cardiac death without evidence of
pre-existing cardiac disease and those who developed a
cardiac event during 2008. The latter group was excluded
as less than 12 months remained until the end of the
study. Reversal of cardiac disease was deﬁned as cessa-
tion of cardiac medications after cardiological review.
Similar criteria to those described for the de novo compo-
nent, with respect to regime exposure were used for
attributing the reversal.
Only descriptive data on the incidence of cardiac-
related deaths, de novo cardiac event and reversal are
reported for DFX. Compliance with the chelation ther-
apy and dosing were not assessed or taken into account
for the purposes of this study.
Statistical analysis
Continuous variables are presented as mean ± SD while
categorical variables are described using absolute and rel-
ative frequencies. For ferritin and time of exposure in sur-
vival analysis median and interquartile range (IQR) are
also reported. Hypotheses on whether the mean of a con-
tinuous variable differed signiﬁcantly from that of at least
one other group were tested by analysis of variance (ano-
va). Whenever multiple hypotheses testing occurred, the
signiﬁcance level was corrected by the Bonferroni method
(0.05 divided by the total number of comparisons). Cate-
gorical variables were tested using Fisher’s exact test.
For the comparison on risk of death between the inter-
vals 1990–1999⁄2000–2008 a Poisson distribution was
utilised. In this case, age-related rates of death were cal-
culated and compared according to each person’s contri-
bution in each age-period.
In the de novo cardiac event analysis a 2 · 3 table
(new cardiac events vs. patients at risk for each of the
three treatment groups) was constructed for each calen-
dar year and the respective probabilities (risk) along with
the exact 95% conﬁdence intervals (C.I.) were reported.
Subsequently, the 10 -yr data were combined. From
these combined data, the comparisons of the probabili-
ties of experiencing an event among the three treatment
groups were performed by logistic regression and the rel-
ative risks are reported as odds ratios (ORs) and 95%
C.I.s. Age, gender and level of haemosiderosis were
assessed as potential confounders in the ﬁnal logistic
regression. A small number of treatment groups either
had few or no de novo cardiac events. For this reason it
was necessary to perform an exact logistic analysis to
derive ORs and 95% C.I.s (15). To report incidence rates
of de novo cardiac events for each regime, we used a time
to event method and the event was attributed to the
regime the patient was taking on the date of the event.
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between regimes was also used for the assessment of
improvement. This included a 2 · 3 table (patients
improved vs. patients with cardiac disease for each of the
three treatment groups) for each calendar year and a
comparison with logistic regression of the 9 yr combined
data. A rate was also calculated.
To test whether the risk of dying from cardiac compli-
cation differs signiﬁcantly among the three treatment
groups, we applied a time to event approach with an
exact Poisson regression model, to overcome the difﬁ-
culty of the presence of zero events in several sub-groups.
The starting point was the 1 January 1999. After that
time point, whenever a patient changed regime a new
record was generated and the time was measured from
the start for as long as the patient remained on the new
regime. In addition the mean ferritin levels during the
time period of each record as well as the age at the end
of each record was recorded. In this way the majority of
patients contributed information to more than one
regime, allowing for time variation in treatment, ferritin
levels and age. The end point was the 31 December 2008
or the date of death from cardiac complications, which-
ever occurred ﬁrst. Patients who died of non-cardiac-
related causes or underwent bone marrow transplanta-
tion were considered censored observations at the time
of death or the procedure.
All data were entered in a Microsoft Access database
and statistical analysis was performed using stata 11.0
(StataCorp. College Station, TX, USA).
The Ethics Committee of the hospital approved per-
mission for medical review, waiver of informed consent
and anonymous publication of data according to the
Declaration of Helsinki.
Results
Patient characteristics
For the analysis of the risk of cardiac-related deaths, 597
patients (51.6% males) were included for the time period
of 1990–1999 and 527 patients (49.5% males) were
included in the period 2000–2008.
For the de novo cardiac event component, a total of
354 patients were included, 346 as from the 1 January
1999, while eight additional patients reached the age of
10 yr during the study period and were progressively
included. A total of 63 de novo cardiac events were
recorded. Table 1 demonstrates the demographic data
for all patients.
For the improvement component, 86 persons were
included in the analysis. This group consisted of the fol-
lowing: (i) twenty-nine patients who had a history of car-
diac disease before 1999 and were not included in the de
novo event component. (ii) Two patients who developed
a cardiac event during the study period but were not
included in the de novo component as they had no car-
diac assessments until the diagnosis of their heart decom-
pensation. (iii) From the 63 new events, 55 were included
in the improvement component. One was excluded as his
cardiac event occurred during 2008, while seven patients,
who died suddenly from cardiac causes and who had no
evidence of pre-existing cardiac disease, were not
included. Demographic data of the patients evaluated in
the improvement component in all regimes are shown in
Table 2.
For each treatment group, the data in Tables 1 and 2
were derived from all the individuals assigned to the par-
ticular regime during the observational period. Thus, a
patient might contribute information to more than one
of the three regimes. For this reason, the sum of patients
in the four groups was greater than the total number of
patients in this study.
Trends in cardiac deaths
Table 3 and Fig. 1 show the risk of cardiac-related death
during 1990–1999 compared to 2000–2008 for the two
age groups of 20–30 and 30–40 yr. There was an approx-
imately threefold signiﬁcant reduction in the second time
interval (2000–2008) in both age groups.
Table 1 Characteristics of patients included
in the de novo cardiac event component
Treatment
group, (N)
Age
1,
mean (SD) Ferritin
2, mean (SD), median (IQR)
Gender
3: males,
n (%)
DFO (343) 21.2 (6.9) 2500 (1653), 2014 (1322–3231) 176 (51.3)
DFP (97) 25.3 (6.8) 2903 (2003), 2453 (1297–4330) 46 (47.4)
Combination (166) 26.7 (6.0) 2551 (1795), 2007 (1206–3678) 79 (47.6)
DFX (118) 26.0 (8.7) 2673 (1765), 2076 (1284–3718) 45 (38.1)
IQR, interquartile range; DFO, desferrioxamine; DFP, deferiprone; DFX, deferasirox.
1ANOVA: F-test = 31.3, P < 0.001. Signiﬁcant comparisons DFP vs. DFO, Combination vs. DFO,
DFX vs. DFO (all P-values <0.001 were statistically signiﬁcant considering 0.05⁄6 = 0.008 as the
conﬁdence level after the Bonferroni correction).
2ANOVA: F-test = 1.4, P = 0.23.
3Fisher’s exact test: P = 0.10.
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Sixty-three (63) de novo cardiac events were recorded.
Table 4 shows the number of patients on DFO, DFP
and Combination in chronological annual order, as well
as the risk of de novo cardiac event for each treatment
group. Logistic regression analysis (Table 5) of the 10 -yr
combined data showed that patients on DFP and Com-
bination had 9.1 times and 23.6 times, respectively, lower
risk of de novo cardiac event compared to DFO. Patients
on any DFP (DFP or Combination) showed 14 times
lower risk compared to the DFO group (95% C.I. 4.3–
45.4, P < 0.001). There was no signiﬁcant difference
between the risk in patients on DFP and Combination.
These results are adjusted for age, gender and level of
haemosiderosis that were shown to be signiﬁcant con-
founding variables in the ﬁnal regression model.
Figure 2 shows the odds ratio of the development of a
de novo cardiac event of DFO compared to the other
two regimes within each grade of haemosiderosis. For
Combination, the effect is similar in all levels of iron
load while for DFP the protective effect is more promi-
nent for patients with severe iron load.
The rates of events according to the regime the
patients were taking at the time of onset of the event
were 3.3 per 100 person-years for DFO (95% C.I. 2.5–
4.2, 58 events median time on DFO = 2.4 yr, IQR = 1–
4.2 yr), 0.3 per 100 person-years for DFP (95% C.I.
0.04–2.2, one event recorded in a patient after 4 yr on
DFP), 0.6 per 100 person-years for Combination (95%
C.I. 0.2–1.7, three events recorded in three patients who
had been for 6 months, 73 and 35 d, respectively, on
combination therapy) and 0.4 for DFX (95% C.I. 0.05–
2.6). For DFV 1 cardiac event was observed over 269
person-years and the patient who experienced the event
was 15 months on DFX.
Improvement component
In all patients with cardiac improvement and a large
number of patients who have not been included as an
improvement, the left ventricular ejection fraction
increased to normal levels (>60%) but they were only
included as an improvement once the cardiologist had
recommended cessation of cardiac medications. Table 6
Table 2 Characteristics of patients included
in the improvement component
Treatment
group, (N)
Age
1,
mean (SD) Ferritin
2, mean (SD), median (IQR)
Gender
3: males,
n (%)
DFO (75) 26.8 (5.7) 2956 (2222), 2511 (1258–4302) 51 (68.0)
DFP (35) 31.0 (6.7) 2252 (2573), 1151 (407–3025) 21 (60.0)
Combination (61) 30.1 (6.2) 2927 (2386), 2135 (1023–3912) 36 (59.0)
DFX (9) 33.9 (6.2) 2332 (1959), 1483 (1155–3009) 5 (55.6)
IQR, interquartile range; DFO, desferrioxamine; DFP, deferiprone; DFX, deferasirox.
1ANOVA: F-test = 8, P < 0.001. Signiﬁcant comparisons (considering 0.05⁄6 = 0.008 as the conﬁ-
dence level after the Bonferroni correction): DFP vs. DFO (P-value = 0.002), Combination vs. DFO
(P-value = 0.004), DFX vs. DFO (P-value = 0.006).
2ANOVA: F-test = 1, P = 0.37.
3Fisher’s exact test: P = 0.65.
Table 3 Age-speciﬁc risk of cardiac death according to decade
Age group (yrs)
1990–1999 2000–2008
Risk ratio (P) Deaths Person-years
Risk (per 1000
person-years) Deaths Person-years
Risk (per 1000
person-years)
20–30 30 1964.5 15.2 14 2079.7 6.7 2.2 (0.0095)
30–40 5 267.5 18.7 8 1415.1 5.6 3.3 (0.052)
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Figure 1 Comparison of annual risk of cardiac death of the years
1990–1999 compared to 2000–2008 stratiﬁed according to age.
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gle calendar year intervals. Logistic regression analysis of
the 9 -yr combined data showed that patients on DFP
were 8.5 times more likely to improve than those on
DFO (OR = 8.5, 95% C.I.: 2.2–32.9, P-value = 0.002)
while those on Combination had a 6.1 time greater likeli-
hood (OR = 6.1, 95% C.I.: 1.7–21.2 P-value = 0.005).
Table 4 Annual risk of de novo cardiac event according to the chela-
tion regime
Year
DFO DFP Comb
Events⁄exposed
1,
% risk (95% C.I.)
Events⁄exposed,
% risk (95% C.I.)
Events⁄exposed,
% risk (95% C.I.)
1999 16⁄338
4.7 (2.7–7.6)
0⁄0 (n.a.) 0⁄0 (n.a.)
2000 8⁄316
2.5 (1.1–4.9)
0⁄2
0 (0–84.1)
2
0⁄4
0 (0–60.2)
2
2001 13⁄282
4.6 (2.5–7.7)
0⁄16
0 (0–20.6)
2
0⁄17
0 (0–19.5)
2
2002 7⁄246
2.8 (1.2–5.4)
0⁄18
0 (0–18.5)
2
0⁄40
0 (0–8.8)
2
2003 5⁄189
2.6 (0.9–6.1)
1⁄42
2.4 (0.06–12.6)
0⁄63
0 (0–5.7)
2
2004 6⁄147
4.1 (1.5–8.7)
0⁄63
0 (0–5.7)
2
0⁄69
0 (0–5.2)
2
2005 1⁄111
0.9 (0.02–4.9)
1⁄58
1.7 (0.04–9.2)
0⁄92
0 (0–3.9)
2
2006 2⁄69
2.9 (0.4–10)
0⁄50
0 (0–7.1)
2
1⁄115
0.9 (0.02–4.7)
2007 1⁄43
2.3 (0.06–12.3)
0⁄35
0 (0–10)
2
0⁄99
0 (0–3.6)
2
2008 0⁄33
0 (0–10.6)
2
0⁄43
0 (0–8.2)
2
0⁄98
0 (0–3.6)
2
DFO, desferrioxamine; DFP, deferiprone.
1Number of persons at risk for de novo cardiac event in each treat-
ment group.
2One-sided, 97.5% conﬁdence interval.
Table 5 Comparison
1 of risk of de novo cardiac event of combined
10 yr data
Variable Comparison Odds ratio 95% C.I. P-value
Treatment
2 DFO vs. DFP 9.1 2.2–38.3 0.003
DFO vs. comb 23.6 3.2–172.1 0.002
Age group 20–30 yr vs. 10–20 yr 1.9 0.9–3.9 0.073
>30 yr vs. 10–20 yr 1.4 0.6–3.7 0.45
20–30 yr vs. >30 yr 1.3 0.6–2.9 0.48
Gender Males vs. females 2.7 1.5–4.9 0.001
Haemosiderosis Moderate vs. mild 1.8 0.9–3.5 0.064
Severe vs. mild 4.1 2.1–7.7 <0.001
Severe vs. moderate 2.2 1.2–4.2 0.014
DFO, desferrioxamine; DFP, deferiprone.
1Logistic regression, the reported odds ratios are adjusted for the
presence of the other variables.
2The other comparisons between the treatment groups were not sig-
niﬁcant.
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Figure 2 Relative risk (odds ratio) of development of de novo cardiac
event – DFO compared to DFP and Comb, within each stratum of
haemosiderosis, as estimated by exact logistic regression analysis.
Numbers on the top of each bar are the odds ratio and the respective
P-value (results adjusted for sex and age).
Table 6 Annual probability of improvement according to the chelation
regime. Irrespective of the regime to which the event was attributed,
patients subsequently may have changed regime explaining the
increasing number of patients in the non-DFO regimes compared to
the number of events that were attributed to those regimes
Year
DFO DFP Comb
Improvements⁄
exposed
1
% (95% C.I.)
Improvements⁄
exposed
% (95% C.I.)
Improvements⁄
exposed
% (95% C.I.)
2000 2⁄39
5.1 (0.6–17.3)
0⁄1
0 (0–97.5)
2
0⁄0 (n.a.)
2001 1⁄42
2.4 (0.06–12.6)
0⁄1
0 (0–97.5)
2
0⁄1
0 (0–97.5)
2
2002 0⁄32
0 (0–10.9)
2
0⁄6
0 (0–45.9)
2
0⁄14
0 (0–20.6)
2
2003 0⁄21
0 (0–16.1)
2
1⁄12
8.3 (0.2–38.5)
2⁄24
8.3 (1–27)
2004 0⁄19
0 (0–17.6)
2
1⁄16
6.2 (0.2–30.2)
0⁄24
0 (0–14.2)
2
2005 0⁄11
0 (0–28.5)
2
2⁄15
13.3 (1.6–40.4)
0⁄34
0 (0–10.3)
2
2006 0⁄7
0 (0–40.9)
2
1⁄14
7.1 (0.2–33.9)
3⁄38
7.9 (1.6–21.4)
2007 0⁄5
0 (0–52.2)
2
3⁄11
27.3 (6–61)
7⁄36
19.4 (8.2–36.1)
2008 0⁄4
0 (0–60.2)
2
1⁄9
11.1 (0.3–48.2)
5⁄29
17.2 (5.8–35.8)
DFO, desferrioxamine; DFP, deferiprone.
1Number of persons with heart disease in each treatment group.
2One-sided, 97.5% conﬁdence interval.
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6.7 times greater chance of improving compared to DFO
(OR = 6.7, 95% C.I.: 2–22.7 P-value = 0.002). The
comparison between DFP and Combination was not sig-
niﬁcant. Age and gender were not signiﬁcant while
increasing level of haemosiderosis reduced the likelihood
of improvement (results available from authors).
The rates of improvement according to the regime the
patients were taking at the time of improvement, were
0.6 per 100 person-years for DFO (95% C.I. 0.1–2.3),
13.9 per 100 person-years for DFP (95% C.I. 7.1–25.1),
6 per 100 person-years for Combination (95% C.I. 3.6–
11.1). For DFX, the one patient with a cardiac event
improved giving a rate of improvement of 6.6 per 100
patient-years (95% C.I. 0.9–46.8).
Incidence of cardiac deaths
After 1999, there were 22 deaths in total over the period
of observation. Twenty were cardiac-related and two
were from other causes (one accident and one thrombo-
embolic event). There were 18 cardiac-related deaths in
the DFO arm over 1900 patient-years (Risk = 9.5⁄1000
patients-years, median time of exposure = 2.6 yr,
IQR = 1.3–3.6 yr), on in the DFP group for 393
patient-years (Risk = 2.5⁄1000 patients-years, the one
death occurred in a patient after 1.3 yr on DFP) and one
in the Combination group over 709 patient-years
(Risk = 1.4⁄1000 patients-years, the one death occurred
in a patient after 4.1 yr on combination therapy). An
exact Poisson regression analysis (adjusted for sex,
degree of haemosiderosis – age not signiﬁcant) showed
the following relative risk (RR) of experiencing a car-
diac-related death: DFO had 6.1 RR and 5.7 RR com-
pared to DFP and Combination, respectively, although
the results were marginally non-signiﬁcant (P-values
0.058 and 0.073, respectively). Comparison between DFP
and Combination was not signiﬁcant. The RR for DFO
compared to DFP and Combination patients together
(i.e. any DFP) was 5.2 and the P-value was 0.009. There
were no deaths in patients taking DFX over a total of
283 patient-years.
Discussion
This study assessed whether new therapeutic options for
the management of thalassaemia have had an impact on
cardiac disease free survival in a large group of patients
attending one clinic. It is obvious that the risk of cardiac
disease has decreased signiﬁcantly after the start of this
millennium as shown by the comparison of the 1990–
1999 and 2000–2008 time intervals, similar to reports
from other centres (8, 9). The argument though, that per-
haps all patients who were more likely to present cardiac
problems have died, does not hold. Our analysis ensures
that similar age groups are compared, thereby, reducing
the risk of including patients more vulnerable to cardiac
disease in the 1990–1999 time period. This improvement
can be attributed to the greater availability of choices in
chelation therapy, the ability to assess cardiac and hepa-
tic iron by MRI, improvement in compliance associated
with the knowledge of the degree of cardiac and hepatic
iron and tailoring of chelation therapy. The greater abil-
ity of DFP to remove cardiac iron and increase ejection
fraction (16) is likely to have played a signiﬁcant role in
this improvement. Its theoretical ability to reduce labile
cellular iron and thereby reduce free radical activity is
also likely to play a role (17). This cardio-protective
effect was also shown in a recent randomised study in
which patients on DFO had a 27.78 greater risk of car-
diac death compared to patients receiving DFP or Com-
bination (18). This together with our data clearly
demonstrates that the decrease in the incidence of car-
diac-related deaths is more prominent in patients receiv-
ing any DFP regime. The latter study concluded that the
protective effect of DFP appeared irrespective of the
degree of body iron load. The lower protective effect
found in our study (relative risk of death 5.2) is most
likely because of our policy of changing the treatment of
our patients from DFO to a DFP regime, in contrast to
the randomised study, once we became concerned about
their cardiac function.
The stratiﬁed analysis of the events shows that the car-
dio-protective effect of DFP and Combination, com-
pared to DFO, persists at all levels of haemosiderosis, as
assessed by ferritin levels. This analysis was applied only
to assess whether there was an advantage of the DFP
and Combination compared to DFO and whether this
advantage was the same at all levels of haemosiderosis.
Although the reduced power because of stratiﬁcation did
yield statistically signiﬁcant differences in only some
comparisons, the trends seen are of particular interest.
Even patients with mild haemosiderosis on DFO experi-
ence higher risk of cardiac disease compared to those on
the other two regimes. This protective effect is more
prominent with Combination. This indicates that patients
who until recently were considered safe from developing
cardiac disease have the potential to reduce their cardiac
risk even further with the appropriate choice of chelation
regime. A striking result, with respect to DFP, is that the
protective effect reaches its maximum in patients with
severe iron load and appears to be equal to that of com-
bination therapy.
The applied criteria to the diagnosis of a cardiac event
and its attribution to the chelation regime are similar to
those in other studies (10, 11). It is clear that the regimes
that became available after the year 2000 have had a sig-
niﬁcant impact on the reduction of cardiac morbidity.
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with DFO, DFP (16), Combination (19) and DFX (20)
that assessed the clearance of iron from the heart based
on CMR studies. Between the DFP and Combination,
we could not discern any statistically signiﬁcant differ-
ence in the risk of de novo cardiac events. A number of
studies have shown that irrespective of acceptable chela-
tion with DFO as demonstrated by mean ferritin levels,
the incidence of cardiac morbidity remained a clinical
issue. In some patients, even low levels of ferritin were
associated with excess cardiac iron as assessed by CMR
(21, 22). These recent studies have further demonstrated
that both ferritin levels and LIC have no clinical rele-
vance with respect to their ability to predict the degree
of cardiac iron loading.
The observations of signiﬁcance with respect to level of
haemosiderosis, gender and age as confounding factors
with respect to cardiac morbidity indicate that studies
based on clinical observations which lack randomisation,
should take these three parameters into account so that
the results will be accurate.
The patients on DFP and Combination showed a
signiﬁcantly greater probability of reversing their car-
diac dysfunction compared to DFO. Some patients
showed an improvement in their cardiac function while
remaining on DFO. It is well known and reported that
intensiﬁcation of DFO therapy is capable of reversing
even overt cardiac failure (23–25). The ability to
improve cardiac function with DFP (16) and Combina-
tion (26) are as expected and are compatible with other
studies, clinical experience and case reports (27–29).
The reticence of the cardiologists to cease the medica-
tions once there was a sustained improvement in car-
diac function could have lead to an underestimation of
the numbers of patients who showed improvement. Our
intention was not to include patients as improved, even
with possible minor residual cardiac dysfunction. There-
fore, in the presence of overt cardiac failure, the pre-
ferred initial chelation regime should be Combination
or intensive DFO therapy if DFP treatment is contrain-
dicated.
The estimated low rate of de novo cardiac events and
the absence of cardiac-related deaths, in the DFX group
in our Unit are encouraging and to date have not been
reported. They need, however, to be evaluated in the
context of the features of the patients receiving DFX in
our unit. As mentioned earlier, the medication was
preferentially prescribed to patients who had mild iron
load as assessed by ferritin levels and CMR (30). Further
studies that will follow patients over a long period of
time, may conﬁrm the present preliminary results. The
relatively short follow-up period in patients on DFX
does not provide sufﬁcient information to make appro-
priate inferences in the improvement component.
A major limitation in our study as with any clinical
observational study is that treatment is modiﬁed accord-
ing to the patients’ progress. This translates to situations
where therapeutic decisions are made according to signs
of deterioration and perceived risks. In our unit, patients
who were at increased risk of cardiac disease based on
CMR or ferritin levels are selectively prescribed Combi-
nation or intensive DFO. We believe that differences in
the level of iron load which are related to the clinical
decisions and could confound the results have been taken
into account by the stratiﬁcation analysis. With respect
to the assignment criteria as to which regime the patient
was taking at the time of an event, there were two
patients in whom the event was attributed to the previ-
ous regime; not the one they were taking at the time of
the diagnosis of the event. They were only taking the
new regime for a brief period of time (35 and 73 d). It is
likely that the regime changes were made on the basis of
clinical concerns with respect to potential imminent car-
diac disease. However, until the change in regime, they
did not fulﬁl the criteria for characterisation as events.
When the events were attributed to the regime received
at the time of the event, the results showed minor differ-
ences without altering the clinical signiﬁcance. As this
was a clinical observational study, we did not record
compliance or doses of chelation medication, as it is
logistically impossible to calculate the average dose for a
long period of time in which several minor changes could
have been made. We consider the difﬁculties associated
with the use of any prescribed regime as a parameter of
its efﬁcacy. Therefore, poor efﬁcacy is related to possible
poor compliance. This in fact, could be interpreted as a
strong point of this study. In a controlled clinical trial,
compliance is rigidly evaluated. The outcome reported is
what might be expected within a clinical context and
may be more valuable with respect to what a clinician
can expect.
As in our experience, myocarditis usually reverses
within a relatively short period of time. In some cases, it
is associated with previous viral infections but the diag-
nosis can only be made for certain by cardiac biopsy or
on necropsy. It was excluded as a cause of the cardiac
event on the basis of the long period of time needed for
reversal of cardiac dysfunction. For cardiac deaths, with-
out necropsy analysis we cannot be sure that the deaths
were not myocarditis.
We believe that the volume of data on DFP and Com-
bination was satisfactory, albeit less, than that of DFO.
This could have been a potential limitation in terms of
reduced power only, because incorporation of age, gen-
der and level of haemosiderosis in the analysis removed
any confounding effect. Had the results not been statisti-
cally signiﬁcant, we would have not been able to deter-
mine whether the lack of signiﬁcance in the differences
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cally no differences between regimes.
Conclusion
New chelation options in patients with thalassaemia have
reduced cardiac morbidity and mortality. Cardiac deaths
have reduced in many centres throughout the world since
the year 2000. The newer chelation regimes demonstrate
lower risk of cardiac events. In the past, the onset of car-
diac failure in patients with thalassaemia usually pro-
gressed to death within a short period of time. This
study clearly demonstrates that a signiﬁcant proportion
of patients who developed cardiac events, were able to
regain normal cardiac function with appropriate therapy.
The new regimes together with better non-invasive diag-
nostic facilities for identifying both hepatic and cardiac
iron load are expected to improve survival even further
and reduce incidence and severity of complications
caused by haemosiderosis.
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